ABCG1 — When Dietary PUFAs Raise, Not Lower, Cholesterol
ABCG1 (ATP-binding cassette transporter G1 | a membrane-spanning pump that moves
cholesterol and phospholipids from the inner leaflet of cell membranes onto
maturing HDL particles, completing the second step of reverse cholesterol
transport after ABCA1 initiates lipid loading onto nascent HDL)
encodes one of the body's principal cholesterol efflux transporters. Located on
chromosome 21q22.3, ABCG1 is expressed in macrophages, liver, and many other
tissues, where it loads mature HDL particles with surplus cellular cholesterol
for transport back to the liver — a central step in preventing foam cell
formation and atherosclerotic plaque development.
rs4148102 is an intronic variant in ABCG1 that has no known effect on the protein
sequence itself, but its location within an intron has raised the possibility of
subtle effects on ABCG1 splicing, expression, or its response to dietary lipid
signals. What distinguishes this variant is not its baseline effect on cholesterol
but the way it conditions the body's response to high polyunsaturated fatty acid
(PUFA) intake — producing a counterintuitive pattern where a seemingly
heart-healthy dietary pattern raises LDL-cholesterol in AA homozygotes.
The Mechanism
The biological basis for this gene-diet interaction is not fully characterized
at the molecular level. However, ABCG1 transcription is under LXR | liver X
receptor — a nuclear receptor activated by oxysterols and certain fatty acid
derivatives; once activated, LXR drives expression of ABCG1, ABCA1, and other
cholesterol homeostasis genes control.
Polyunsaturated fatty acids and their metabolites serve as LXR ligands and can
modulate its activity. An intronic variant could influence how effectively the
ABCG1 gene responds to these dietary lipid signals — for example, by altering
a regulatory element that fine-tunes LXR responsiveness.
When ABCG1 function is subtly impaired or mis-regulated, cholesterol efflux from
cells to HDL is reduced. Under high-PUFA dietary conditions, which normally
promote LDL receptor upregulation and LDL clearance, the AA variant appears to
interfere with this adaptive response, resulting in paradoxically elevated LDL
and total cholesterol rather than the reduction seen in GG carriers on the same diet.
The Evidence
The primary evidence comes from a
study by Abellán et al. | Abellán R et al. Dietary polyunsaturated fatty acids
may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers
of an ABCG1 gene single nucleotide polymorphism: study in two Spanish populations.
Atherosclerosis, 2011 examining 1,941
participants across two independent Spanish cohorts (the Hortega study, n=1,178,
and the Pizarra study, n=763). In the Hortega population, AA homozygotes consuming
high-PUFA diets had LDL-cholesterol of 149.8 ± 37.9 mg/dL compared to 111.4 ± 32.1
mg/dL in G allele carriers (p=0.005). Total cholesterol diverged similarly (242.1
vs 198.0 mg/dL, p=0.003). Pooling both cohorts strengthened the signal: gene-diet
interaction p=0.006 for total cholesterol, p=0.003 for LDL-cholesterol.
The A allele is relatively uncommon globally (~14.5%), making AA homozygosity
rare (~2% of the population). This limits replication opportunities and explains
why no dedicated follow-up trials exist yet. The evidence level is therefore
emerging — a well-designed two-cohort study, but not yet replicated in independent
populations or mechanistically confirmed in cell-based assays.
Practical Actions
For AA homozygotes, the clinical implication is specific: high-PUFA diets — which
most guidelines recommend as beneficial — may actually raise LDL-cholesterol
in this genotype. Rather than increasing total PUFA from vegetable oils (sunflower,
corn, safflower), focus on pre-formed long-chain omega-3s (EPA and DHA from
fatty fish or supplements) and monitor fasting LDL when making significant
dietary changes. Saturated fat should still be limited — this is not a signal
to increase saturated fat intake. The issue is specifically with high omega-6
PUFA loads from vegetable oils, not with EPA/DHA.
Carriers of one A allele (AG) represent roughly 25% of people. The gene-diet
interaction was strongest in AA homozygotes; AG heterozygotes showed intermediate
patterns in some analyses, but the effect was not consistent across both study
populations. Standard dietary PUFA guidance applies.
Interactions
ABCG1's role in cholesterol efflux depends on the upstream ABCA1 step (rs1044317
is another ABCG1 variant in the cholesterol_lipoproteins category). If both
ABCG1 steps in the efflux pathway are impaired — the initial ABCA1-mediated lipid
loading onto nascent HDL, and the ABCG1-mediated maturation step — the combined
cholesterol efflux deficit could be larger than either variant alone. FADS1
variants (rs174547, rs174537) also interact with this locus biologically: impaired
FADS1 conversion of plant omega-3s to EPA/DHA shifts the circulating PUFA ratio
toward omega-6, which may amplify the LDL-raising signal seen with rs4148102 AA
on high-PUFA diets.
Alla genotyper
Standard PUFA response — no elevated LDL risk from dietary polyunsaturated fats
You carry two copies of the G allele, the common form found in about 73% of people globally. With this genotype, consuming a diet rich in polyunsaturated fatty acids (PUFAs) produces the expected response: no paradoxical LDL elevation. Standard dietary guidance — including replacing saturated fats with unsaturated fats — applies normally.
One copy of the PUFA-interaction allele — modest dietary monitoring warranted
You carry one copy of the A allele and one copy of the G allele, a genotype found in approximately 25% of people globally. The gene-diet interaction between this variant and high-PUFA diets was strongest in AA homozygotes; heterozygous AG individuals showed variable results across the two study populations. Your response to dietary PUFAs may be near-normal, but checking fasting LDL when substantially changing your fat intake is a reasonable precaution.
High-PUFA diets may raise LDL-cholesterol — avoid high vegetable-oil omega-6 loads and monitor lipids
You carry two copies of the A allele, a genotype found in approximately 2% of the global population (and up to ~6% in East Asian ancestry groups, where the A allele is more common). In a study of 1,941 Spanish adults, AA homozygotes consuming high-PUFA diets had LDL-cholesterol readings of 149.8 mg/dL compared to 111.4 mg/dL in G allele carriers — a 38 mg/dL difference — with a significant gene-diet interaction (p=0.003 in pooled analysis). The same pattern held for total cholesterol. This counterintuitive effect means that dietary advice to "replace saturated fat with polyunsaturated fat" may not lower your LDL in the way it would for most people. The mechanism is not fully established, but likely involves impaired ABCG1 transcriptional responsiveness to dietary PUFA signals, reducing cholesterol efflux efficiency and blunting the normal LDL-lowering effect of PUFA consumption. Evidence is at the emerging level — a single two-cohort study without independent replication — so these findings should guide monitoring rather than dramatic dietary overhaul.